<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058757</url>
  </required_header>
  <id_info>
    <org_study_id>NeoadjMitomycin-C</org_study_id>
    <nct_id>NCT03058757</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation</brief_title>
  <official_title>The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation in Non-muscle Invasive Bladder Cancer Patients: Prospective, Randomized, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical
      mitomycin-C instillation in non-muscle invasive bladder cancer patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Intervention Model: Single Group Assignment Masking: Open Label

      Primary Outcome Measures:

      Recurrence-free survival in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group
      and control group.

      Secondary Outcome Measures:

      Progression-free survival in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
      group and control group.

      Time to recurrence in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group and
      control group.

      Change of tumor size after neoadjuvant intravesical mitomycin-C 40mg/20ml instillation.

      Safety of neoadjuvant intravesical mitomycin-C 40mg/20ml instillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group and control group. Recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>1 year</time_frame>
    <description>Pathologic recurrence free survival after transurethral resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group and control group. Progression will be assessed by CT scan.</measure>
    <time_frame>1 years</time_frame>
    <description>Pathologic or radiologi progression free survival after transurethral resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence in neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group and control group. Recurrence will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>1 years</time_frame>
    <description>Period of from transurethral resection to first pathologic recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tumor size after neoadjuvant intravesical mitomycin-C 40mg/20ml instillation. Change of tumor size will be assessed by CT scan and cystoscopic exam.</measure>
    <time_frame>1 years</time_frame>
    <description>Change of tumor size at the time point of diagnostic cystoscope to transurethral resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of neoadjuvant intravesical mitomycin-C 40mg/20ml instillation.</measure>
    <time_frame>six years</time_frame>
    <description>Safety will be assessed by International Prostate Symptom Score (IPSS; 0-7, mildly symptomatic; 8-19, moderately symptomatic; 20-35 severely symptomatic) and treatment delay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant intravesical mitomycin-C 40mg/20ml instillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravesical mitomycin-C 40mg/20ml instillation</intervention_name>
    <description>neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation
one day before surgery
four hours before surgery</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>Mitomycin_C Kyowa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects who will undergo transurethral resection of the tumor after diagnosis of
             bladder cancer

          -  Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed
             as bladder cancer

          -  Normal bone marrow function: Hemoglobin &gt;10 g/dL, ANC &gt;1,500/mm3, platelet
             count&gt;100,000/mm3

          -  Normal renal function: serum creatinine ≤ 1.4 mg/dL

          -  Normal liver function:

          -  Bilirubin ≤ 1.5 times of upper normal limit

          -  AST/ALT ≤ 1.8 times of upper normal limit

          -  Alkaline phosphatase ≤ 1.8 times of upper normal limit

          -  Subjects who voluntarily decided to participate and signed the written informed
             consent

        Exclusion Criteria:

          -  Non-urothelial carcinoma

          -  Muscle invasive bladder cancer

          -  Subjects who underwent intravesical mitomycin-C instillation after diagnosis of
             bladder cancer within 3 years

          -  Prior hypersensitivity reaction history to mitomycin-C

          -  Neurogenic bladder

          -  Subjects who underwent chemotherapy due to any cancer within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Kyung Seo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ho Kyung Seo, M.D.</last_name>
    <phone>82-31-920-1678</phone>
    <email>seohk@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoon Seok Suh, M.D.</last_name>
    <phone>82-10-5019-9807</phone>
    <email>12754@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Kyung Seo, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jinsoo Chung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Han Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Ho Kyung Seo</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

